thymosin beta-4 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-12-03. Anything still debated is marked as such rather than presented as settled.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
| Property | Value | Notes |
|---|---|---|
| Name type | Commercial trade name | Not a systematic chemical identifier |
| Parent peptide | Thymosin beta-4 | 43-residue natural peptide |
| Common fragment sequence | LKKTETQ | Maps to part of the actin-binding region |
| Molecular size class | Roughly 0.8-1.0 kDa | Depends on exact fragment and terminal modification |
| Regulatory status | Prohibited in sport | Grouped with peptide hormones in many frameworks |
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
== Etymology and central beliefs == Effective accelerationism, a portmanteau of "effective altruism" and "accelerationism", is a fundamentally techno-optimist movement. According to Guillaume Verdon, one of the movement's founders, its aim is for human civilization to "clim[b] the Kardashev gradient", meaning its purpose is for human civilization to rise to next levels on the Kardashev scale by maximizing energy usage. To achieve this goal, effective accelerationism wants to accelerate technological progress. It is strongly focused on artificial general intelligence (AGI), because it sees AGI as fundamental for climbing the Kardashev scale. The movement therefore advocates for unrestricted development and deployment of artificial intelligence. Regulation of artificial intelligence and government intervention in markets more generally is met with opposition. Many of its proponents have libertarian views and think that AGI will be most aligned if many AGIs compete against each other on the marketplace. The founders of the movement see it as rooted in Jeremy England's theory on the origin of life, which is focused on entropy and thermodynamics. According to them, the universe aims to increase entropy, and life is a way of increasing it. By spreading life throughout the universe and making life use up ever increasing amounts of energy, the universe's purpose would thus be fulfilled.
Faure Essozimna Gnassingbé (French pronunciation: [fɔʁ esozimna ɲasiŋɡbe]; born 6 June 1966) is a Togolese politician who has led Togo since 2005, first as the fourth president until 2025 and then as president of the Council of Ministers. A member of the ruling Union for the Republic (UNIR), he is the son of the third president, Gnassingbé Eyadéma. Born in Afagnan, Gnassingbé studied in the United States and France before joining the Rally of the Togolese People (RPT) in 1990. He was appointed by his father as Minister of Equipment, Mines, Posts, and Telecommunications, serving in these roles from 2003 to 2005. Following Eyadéma's death in 2005, Gnassingbé was immediately installed as president with support from the army and was elected president of the National Assembly to further legitimise his succession. However, doubts regarding the constitutional legitimacy of the succession led to heavy regional pressure being placed on Gnassingbé, and he subsequently resigned on 25 February. He then won a controversial presidential election on 24 April, and was sworn in as president. Gnassingbé further ran for three more terms in 2010, 2015 and 2020, after a 2019 constitutional amendment which allowed him to run for two more terms. In 2024, Gnassingbé once again amended Togo's constitution, transferring most of the presidency's powers to the position of prime minister, which was officially reconstituted as "president of the Council of Ministers", nominally turning Togo from a presidential republic into a parliamentary one.
== Occurrence == Realgar most commonly occurs as a low-temperature hydrothermal vein mineral associated with other arsenic and antimony minerals. It also occurs as volcanic sublimations and in hot spring deposits. It occurs in association with orpiment, arsenolite, calcite and barite. It is found with lead, silver and gold ores in Hungary, Bohemia and Saxony. In the US it occurs notably in Mercur, Utah; Manhattan, Nevada; and in the geyser deposits of Yellowstone National Park. After a long period of exposure to light, realgar changes form to a yellow powder known as pararealgar (β-As4S4). It was once thought that this powder was the yellow sulfide (orpiment), but is a distinct chemical compound.
Sources: en.wikipedia.org
=== Pharmacokinetics === Steady-state levels of clascoterone occur within 5 days of twice daily administration. At a dosage of 6 g clascoterone cream applied twice daily, maximal circulating levels of clascoterone were 4.5 ± 2.9 ng/mL, area-under-the-curve levels over the dosing interval were 37.1 ± 22.3 h*ng/mL, and average circulating levels of clascoterone were 3.1 ± 1.9 ng/mL. In rodents, clascoterone has been found to possess strong local antiandrogenic activity, but negligible systemic antiandrogenic activity when administered via subcutaneous injection. Along these lines, the medication is not progonadotropic in animals. The plasma protein binding of clascoterone is 84 to 89% regardless of concentration. Clascoterone is rapidly hydrolyzed into cortexolone (11-deoxycortisol) and this compound is a possible primary metabolite of clascoterone based on in-vitro studies in human liver cells. During treatment with clascoterone, cortexolone levels were detectable and generally below or near the low limit of quantification (0.5 ng/mL). Clascoterone may also produce other metabolites, including conjugates. The elimination of clascoterone has not been fully characterized in humans.
Action and Adventure – Fable II Artistic Achievement – LittleBigPlanet Best Game – Super Mario Galaxy Casual – Boom Blox Gameplay – Call of Duty 4: Modern Warfare Handheld – Professor Layton and the Curious Village Multiplayer – Left 4 Dead Original Score – Dead Space Sports – Race Driver: Grid Strategy – Civilization Revolution Story and Character – Call of Duty 4: Modern Warfare Technical Achievement – Spore Use of Audio – Dead Space BAFTA One's to Watch Award (in association with Dare to Be Digital) – Boro-Toro GAME Award of 2008 – Call of Duty 4: Modern Warfare Academy Fellowship – Nolan Bushnell
== See also == Allergy Diamine oxidase Food intolerance Granulocyte Histamine intolerance Histamine N-methyltransferase or HNMT Histamine List of distinct cell types in the adult human body Mast cell activation syndrome Mastocytosis
Sources: en.wikipedia.org
The strains are small and within the elastic limit. The surfaces are continuous and non-conforming (implying that the area of contact is much smaller than the characteristic dimensions of the contacting bodies). Each body can be considered an elastic half-space. The surfaces are frictionless. Additional complications arise when some or all these assumptions are violated and such contact problems are usually called non-Hertzian.
==== Bridges ==== Albany has both the Ellsworth Street Bridge which was constructed in 1926 and the Lyon Street Bridge that was constructed in 1973. They are both two-lane bridges that make up part of U.S. Route 20. The two bridges connect Linn to the south with Benton county in the north as they pass across the Willamette River. this makes up the major connection of downtown Albany with the north end of town and to Corvallis.
== Epidemiology == Diabetes is rare in cats younger than five years old. Typically, affected cats are obese. Burmese cats in Europe and Australia have increased risk of developing diabetes; American Burmese cats do not have this increased risk due to genetic differences between American Burmese and Burmese in other parts of the world.
==== Transport through the nuclear membrane ==== The actin sequence does not contain a nuclear localization signal. The small size of actin (about 43 kDa) allows it to enter the nucleus by passive diffusion. The import of actin into the nucleus (probably in a complex with cofilin) is facilitated by the import protein importin 9. Low levels of actin in the nucleus seems to be important, because actin has two nuclear export signals (NES) in its sequence. Microinjected actin is quickly removed from the nucleus to the cytoplasm. Actin is exported at least in two ways, through exportin 1 and exportin 6. Specific modifications, such as SUMOylation, allows for nuclear actin retention. A mutation preventing SUMOylation causes rapid export of beta actin from the nucleus.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.
Published work usually examines actin binding, cell migration and tissue repair endpoints in cell and animal models. Findings are generally described as preliminary, and controlled human data remain limited.
Because TB-500 is a trade name rather than a chemical identifier, different vendors and papers may attach it to different fragment lengths. Checking the stated sequence is the practical way to resolve the ambiguity.
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.